We performed a prospective, randomized, placebocontrolled, double-blind trial to assess the efficacy of aprotinin in 61 children (median age 3.7 yr) undergoing reoperative open heart surgery (OHS). Three demographically similar groups were studied: large-dose aprotinin (ALD), small-dose aprotinin (ASD), and placebo (I'). Over the first 24 postoperative hours fewer patients in the aprotinin groups received packed red cells (ALD, 53%; ASD, 89%; and I', 95%; P = O.OOl), platelets (ALD, 32%; ASD, 50%; and P, 65%; P = 0.04), and fresh frozen plasma (ALD, 16%; ASD, 17%; and I', 60%; P = 0.003) than placebo patients. Most importantly, aprotinin patients had fewer exposures to banked blood components (ALD, median 1 U; and ASD, median 2 U) than P (median 6 U; P = O.OOl), with no difference in overall complication rate. Use of aprotinin was associated with a savings in the patient charges for blood components, operating room time, and duration of hospitalization.
In conclusion, aprotinin decreased the number of units of banked blood components used during the first 24 postoperative hours in reoperative pediatric OHS. Aprotinin thus decreases the risks associated with exposure to banked blood components and reduces hospital charges. (Anesth Analg 1996; 83:1193-9) I n adults, use of aprotinin has been shown to be effective in reducing the volume of mediastinal shed blood (MSB) and the transfusion of banked blood components in reoperative coronary revascularization surgery (l-4) . Subsequent studies have demonstrated beneficial effects of aprotinin for adults who have been receiving aspirin therapy (5), and who are septic or have endocarditis at the time of open heart surgery (OHS) (6). The benefits of aprotinin in pediatric OHS are uncertain, however, especially given the high cost of the drug.
In a series of randomized, placebo-controlled trials, Boldt et al. (7) (8) (9) were unable to confirm a salutary effect of aprotinin on either blood loss or exposure to blood components in children. Boldt described a significant change in thrombomodulin plasma level but no change in protein-S, protein-C, or thrombinl antithrombin III complex levels (9). However, children undergoing repeat OHS procedures (7-9), the procedure in which aprotinin was the most efficacious in adult trials, were specifically excluded (2) (3) (4) 6) .
In contrast, several groups describe potential beneficial effects of aprotinin in pediatric OHS. Dietrich et al. (10) describe reductions in early postoperative mediastinal drainage. In another study, Herynkopf et al. (11) were unable to detect a difference in blood loss, although they noted that homologous donor exposure was decreased by about half in the patients who received aprotinin. In a trial using historical controls, Elliott and Allen (12) noted a decrease in the time from separation of the patient from cardiopulmonary bypass (CPB) to the end of skin closure in patients who received aprotinin. A small study of children undergoing repair of tetralogy of Fallot showed a significant decrease in the total volume of blood loss and blood transfused (13). The most recent study by Penkoske et al. (14) , showed a decrease in blood loss, time to chest closure, volume of transfusions, and number of units transfused. However, this study was not blinded and historical controls were used.
Due to the differences in aprotinin dosage regimens, the methods used in monitoring heparin effect and neutralization, and the variety of patient conditions studied among the various trials, the usefulness of the Anesth Analg 1996;83:1193-9 earlier results is difficult to assess. In reviewing some of these data, Edmunds (15) takes a conservative approach, noting that "aprotinin seems to be less effective in infants and small children; thus a strong recommendation for the drug cannot be made on the basis of current data." The current trial was undertaken to target a specific group, children undergoing repeat OHS who are considered to be at high risk for hemorrhagic complications.
We hypothesized that aprotinin used in this setting would decrease the volume of blood loss after OHS. The effectiveness of aprotinin, however, would be less important if banked blood component unit exposure or costs were not simultaneously decreased (16) . The goals of the present study, therefore, were to assess the effect of aprotinin on postoperative blood loss, need for transfusion of banked blood components, and overall blood product cost in children undergoing reoperative OHS.
Methods
This study protocol was approved by our institutional review board. Informed consent was obtained from the patient's parents or legal guardian. Between July 1993, and October 1995, 61 patients admitted to C. S. Mott Children's Hospital for repeat OHS for congenital heart disease were recruited. Patients were excluded from the study for the following reasons: age less than 1 mo, evidence of renal insufficiency or failure on the basis of preoperative serum creatinine levels (>0.8 mg/dL), known congenital renal anomalies that could lead to renal insufficiency, use of nonsteroidal antiinflammatory drugs or aspirin within 5 days of surgery, preexisting hemostatic abnormalities, parent prohibition of use of blood products for religious reasons, or a history of aprotinin allergy. The patients were randomized in a double-blind fashion to receive one of three drug doses: aprotinin large-dose (ALD) (240 mg/m' intravenous [IV] bolus and in the extracorporeal circuit prime, followed by an lV infusion of 56 mg * mm2 . hhi), smalldose (ASD) (120 mg/m' IV bolus and in the extracorporeal circuit prime, 28mg*mP2. followed by an IV infusion of h-i), or an equal volume of 0.9% saline as a placebo (I'). Th e surgical procedures were each performed by one of two surgeons.
Anesthesia was induced with ketamine 5-10 mg/kg and glycopyrrolate 10 pg/kg intramuscularly, to aid in obtaining IV access. A combination of fentanyl, midazolam, pancuronium, and a volatile drug was used for maintenance anesthesia. After induction of anesthesia and the insertion of IV and intraarterial cannulas, a 1-mL test dose of the study drug was given IV. The patients were observed for 10 min for any untoward res (171.5 r onse. If none occurred, a loading dose mL/m > was infused IV over 20 min and followed by a continuous IV infusion at a rate of 40 mL * m-' . h-l. Study drug was prepared by the manufacturer so that it could not be differentiated by odor or color and so that, when administered on the basis of volume, the appropriate drug dose was delivered. The infusion was discontinued at the end of the operation, just prior to transport of the patient to the intensive care unit (ICU).
Anticoagulation was monitored in all patients using the Medtronic Hemotec Hepcon Hemostasis Management System (Englewood, CO). The response of each individual patient to heparin was initially measured by determining the in vitro heparin dose response before administration of heparin. From this doseresponse curve, the target heparin concentration in whole blood required to maintain the kaolin activated clotting time 2480 s was calculated. During CPB, the predetermined target heparin concentration was maintained by estimation of whole blood heparin concentration using a heparin-protamine titration. Porcine mucosal heparin (Elkins-Sinn, Inc., Cherry Hill, NJ) was used for anticoagulation during CPB for all patients. The heparin was neutralized with protamine (Elkins-Sinn, Inc.) after the patient was separated from CPB. The protamine was administered based on the amount of circulating heparin estimated by heparinprotamine titration performed near the completion of rewarming, when the nasopharyngeal temperature reached 35°C. The process of heparin reversal was repeated until no circulating heparin was detected.
Standard criteria for transfusion of banked blood and blood components were used in both the operating room (OR) and ICU settings. The ICU was not informed of the study so that standard practice would be continued. The target hematocrit in patients with cyanotic morphologies was 40%-45%; and in patients with noncyanotic morphologies, 35%-40%. Platelets were transfused for counts <105/mm3, fresh frozen plasma for prothrombin time >15 s and a partial thromboplastin time ~40 s, and cryoprecipitate was given for fibrinogen ~120 mg/dL. The surgeons, who were blinded to the treatment, assessed the appearance of the field prior to closure of the sternum as being "drier than expected," "as expected," or "wet." The patients were observed for 12 days or until discharge, during which time laboratory results, complications, blood products received, and the volume of MSB were recorded. Patients were excluded from data analysis if they required reexploration for excessive surgical bleeding, developed major postoperative bleeding from a site unrelated to the surgery, or died within 24 h of surgery. The use of surgical "glue" (a mixture of cryoprecipitate and CaCl,) was considered a donor exposure for the purpose of data analysis.
When adult mediastinal drainage data were applied (1,2), the estimated sample size required for an 80% probability of detecting a 25% reduction in the volume of mediastinal drainage, assuming a type I error rate To determine whether the drug groups differed with respect to the proportion of patients who received banked packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate, the data were analyzed using the 2 statistic. The paired t-test was used to compare pre-with postoperative laboratory values. The significance of the relationship between the volume of MSB and the volume of packed red blood cell transfusion was determined by linear regression analysis. The Kruskal-Wallis test was used to test the significance of the number of exposures to blood products the groups received. A continuity-corrected Fisher's exact test was used to compare the surgeons' assessments of the appearance of the surgical field and complication rates. All tests were two-tailed and considered significant when P 5 0.05.
Results
Demographic data for the study population are summarized in Table 1 . The study was stopped after enrollment of 61 patients because preliminary examination of the results from patients ineligible for this study indicated significant differences in blood loss between patients who received aprotinin and those who did not. Therefore, the authors decided to examine the data prior to completion of the planned 165 patients. Four of the original 61 patients enrolled were excluded from analysis. One patient had antithrombin III deficiency, two patients experienced surgical bleeding requiring mediastinal reexploration (both patients had received ALD), and one patient could not be separated from CPB. Data from patients requiring mediastinal reexploration were excluded only if a documented site amenable to surgical repair was located.
Although the operations were diverse and the CPB times varied widely, there were no significant differences among the groups (Tables 1 and 2) with respect to CPB, aortic cross-clamp, and deep hypothermic circulatory arrest durations, volume of packed red blood cells used in the CPB circuit prime, and the volume of perfusate infused at the end of the CPB. However, significantly more female patients were randomized to the I' group. The groups were not different with respect to the proportion with cyanotic (ALD, 74%, ASD, 78% and I', 85%), versus acyanotic morphologies (ALD, 26%, ASD, 22%, and I', 15%; P = 0.67) or the proportion of procedures performed by each surgeon (ELB, ALD 95%, ASD 89%, and P 80%; P = 0.36; Table 1 ). None of the patients received desmopressin or aminocaproic acid. Only two patients received 6% hetastarch in the extracorporeal circuit prime (one ALD and one I'>.
The time from separation from CPB to final skin closure was 47 -t 11 min for ALD, 48 + 19 min for ASD, and 60 t 27 min for I' (P = 0.10). The surgeon's assessment of the appearance of the field was "drier than expected" more frequently in ALD (61%) and ASD (40%) patients than in I' patients (23%, P = 0.03, Table 3 ). Surgical "glue" was used in 26% of the ALD group, 28% of the ASD group, and 50% of P group (P = 0.2). D'ERRICO ET AL.
ANESTH 1996;83:1193-9 The volume of blood loss in the OR (documented by the amount of MSB charted on arrival in the ICU) and over the first 24 postoperative hours was not significantly different among the groups of patients: ALD, 2.3 + 1.8 mL/kg and 27 Ifi: 19 mL/kg; ASD, 2.4 & 2.0 mL/kg and 35 + 28 mL/kg; and I', 5.9 t 10.2 mL/kg and 44 !Z 39 mL/kg; P = 0.15 and P = 0.26, respectively (Figure 1) . The volume of blood loss over the first 24 postoperative hours normalized to the patient weight displayed a strong relationship to the volume of packed red blood cells transfused over the same period of time (? = 0.21, n = 56, P < 0.001).
Over the first 24 postoperative hours, fewer patients in the ALD and ASD groups received packed red blood cells than P patients (ALD 53%; ASD 89%; and I' 95%, P = 0.001). Similarly, fewer of the aprotinin patients received other blood components: 32% of ALD patients and 50% ASD patients received platelets, whereas 65% of P patients received platelets (P = 0.04); 16% of ALD patients and 17% of ASD patients received fresh frozen plasma, whereas 60% of P patients received fresh frozen plasma (P = 0.003): and 18% of ALD, 16% of ASD, and 18% of P patients received cryoprecipitate (P = 0.23). Over the first 24 postoperative hours, ALD (median 1, range O-13) and ASD (median 2, range O-12) patients had significantly fewer exposures to banked blood component units than I' patients (median 6, range O-11; P = 0.001; Figure 2 ). These differences were significant when the ALD and P (P = 0.0005) and ASD and P (P = 0.006) groups were compared, but not when the ALD and ASD groups were compared (P = 0.44).
The largest homogeneous group of patients in this study was the children undergoing the Fontan procedure (n = 21). All of these operations were performed by the same surgeon (ELB). When the blood component unit exposures data were analyzed, the ALD (median 0, range O-1) and ASD (median 2, range l-3) patients again had significantly fewer separate donor ANESTH exposures than I' patients (median 6, range l-12). No difference was detected between groups in the total volume of mediastinal drainage (ALD 215 5 118 mL/ kg; ASD 281 2 125 mL/kg; and P 262 + 149 mL/kg; P = 0.67). Blood urea nitrogen and creatinine were observed for 5 days and compared to the preoperative values for each patient. The blood urea nitrogen did not change significantly from the preoperative baseline value during this time period, except for the fourth postoperative day when it was significantly greater in the P patients (20.3 ? 14.4 ) than the preoperative baseline value (12.1 2 5.3; P = 0.04). This difference disappeared by the fifth postoperative day. The creatinine levels were significantly lower than the preoperative baseline values (0.44 + 0.10) in the ASD patients on postoperative Days 3 (0.38 5 0.06; P = 0.01) and 4 (0.36 + 0.05; P = 0.001). Again, these differences disappeared by postoperative Day 5.
The groups did not differ significantly with respect to the overall number of complications (including mortality). Of the three patients who died 224 h postoperatively, two received I' and one received ALD. Of four patients who had significant cardiac dysrhythmias, two were ALD patients and two were ASD patients. One of these patients went on to require a permanent pacemaker. A total of three neurological events occurred, two in ALD patients and one in a P patient. These events consisted of temporary paraplegia and aphasia in two patients and encephalopathy in the third, all of which resolved by the time of discharge from the hospital. Once again no statistically cost of drug = average iatient charge for aprotinin; cost of operating room (OR) time = average patient charge for the time it took from separation from cardiopulmonary bypass to chest-closure; cost of blood products = average patient charge for all blood products transfused for the first 24 postoperative hours; cost of hospital stay = patient charge for the extra days spent in the hospital (>14 days). significant differences were found regarding complications in this relatively small sample.
The patient is charged $150 for each 200-mL bottle of drug in our institution. The approximate patient charge for 15 min of OR time is $1250; for 1 U of packed red blood cells, $200 and for 1 U of platelets, $120; and for 1 U of fresh frozen plasma, $230. The blood product charge was calculated for each patient who received aprotinin ($634 2 609) or placebo ($2371 5 4350; P = 0.02). Aprotinin patients spent on average 15 min less in the OR, received fewer units of blood products, but incurred the additional charge for aprotinin. Nevertheless, they accrued $2236 less on average in OR, blood component, and drug charges overall (P = 0.015) than the placebo patients. As a group, the patients in the present study required 58.3 + 53.3 h of positive pressure ventilatory support and remained in the ICU for 4.6 & 3.3 days. The length of postoperative stay for ALD patients was 15 ? 12 days; for ASD, 14 ? 10 days, and for placebo, 17 f 14 days (P = 0.74). These differences were not statistically significant (Table 4 ).
Discussion
Our results demonstrate that the use of aprotinin in children undergoing reoperative OHS is associated with a decrease in both the proportion of patients receiving banked blood component transfusions and the number of exposures to different units of banked blood components over the first 24 postoperative hours. The time from the end of CPB to chest closure was shortened with the use of aprotinin, simultaneously decreasing OR and hospital charges. These results suggest that aprotinin was both efficacious and cost effective in this sample.
With recent advances in pediatric cardiac surgery, many children undergo multiple-stage procedures and are exposed to many units of donated blood products, particularly after operations requiring repeat sternotomy and CPB. Repeated exposures to banked D'ERRICO ET AL. AI'ROTININ IN PEDIATRIC REPEAT HEART SURGERY ANESTH ANALG 1996; 83:1193-9 donor units of blood and blood components are associated with an increased risk of infection with non-A, non-B, non-C hepatitis, and possibly with human immunodeficiency virus-a risk which is compounded with each additional exposure (17) (18) (19) . Repeated exposure to multiple donor units also increases the likelihood of formation of abnormal antibodies, making subsequent cross-matching more difficult and timeconsuming (20). Thus, even taken from the narrow perspective of conservation of banked blood components, efforts to minimize their administration to children would be advantageous.
Although the actual volume of blood loss was not different, the patients who received aprotinin were transfused fewer banked units of blood components over the first 24 postoperative hours. Two mechanisms may be offered to explain this apparent discrepancy. First, it is possible that aprotinin may contribute to enhanced hemodynamic stability in the postoperative period by attenuating the intensity of the inflammatory response to CPB (21). As a kallikrein inhibitor, aprotinin has been shown to inhibit the conversion of kininogen to kinin, thus preventing accompanying decreases in total peripheral vascular resistance (22) . Aprotinin may attenuate the increased peripheral vascular permeability and fibrinolysis which occurs as a result of CPB, thus contributing to greater overall hemodynamic stability in the postoperative period (10, 22) . Second, the number of separate banked units transfused may be a more sensitive indicator of the severity of bleeding than the actual volume of mediastinal drainage.
The role of aprotinin in pediatric OHS has been controversial due to the conflicting results of the previous clinical outcome information.
These confusing results may have been due, in part, to the inconsistent manner, from study to study, in which heparin effect and neutralization were monitored, to the inconsistent manner in which aprotinin itself was administered, and to the fact that children undergoing repeat OHS were not identified as a separate population. Dose regimens for children have been extrapolated from those used in adults, the validation of which remains unproven and was beyond the scope of the present study.
The results of the present study indicate a decrease in the use of banked blood components coupled with a decrease in OR time and hospitalization, suggesting that, despite its relative expense, aprotinin may be cost effective. In fact, calculated hospital charges were on average $4000 less in aprotinin than in placebo patients. The present data included only those charges billed by the hospital to the patients, and did not measure differences in the true cost of services rendered. No satisfactory method is available to determine actual hospital costs in our institution.
None of the currently available clinical trials of aprotinin performed in children addresses this issue of cost effectiveness. From the perspective of patient charges versus benefits, the present results would seem to favor the small-dose regimen.
The number of patients in the present study is too small to draw conclusions about the safety of aprotinin, although there were no clear indications that aprotinin use was associated with increased morbidity or mortality risk. Allergic reactions, hypercoagulability, hemodynamic instability, cardiac dysrhythmias, and adverse renal affects are still of concern (23-25). Although some studies have advised caution in using aprotinin during procedures in which deep hypothermic circulatory arrest is used routinely because of theoretical risks related to anticoagulation and in vivo clotting during the time when the circulation is stopped, no clear thrombotic complications were observed in our patients. Two of the three neurological complications occurred in patients who received ALD and all patients with significant dysrhythmias received aprotinin.
The neurological complications, however, occurred in patients with prolonged CPB times, or in whom deep hypothermic circulatory arrest was used. All patients at our institution who receive aprotinin for a second time are pretreated with diphenhydramine and cimetidine. In this era of managed health care and reduction of medical expenditures, cost-effective patient-care modalities will likely succeed. In our institution, aprotinin is primarily used in children undergoing repeat OHS. Aprotinin has been shown to decrease blood loss and to have a significant impact on blood bank use in adults undergoing nonprimary myocardial revascularization surgery (2) (3) (4) 6) . Although earlier information would tend to discourage the use of aprotinin in children undergoing OHS, our data suggest that for a specific group of children, namely, those undergoing reoperative OHS, aprotinin can provide a cost-effective means of limiting banked blood unit transfusions and, thereby, decrease the risks that accompany exposures to multiple blood components. 
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